Business Wire - June 25, 2002
The paper discusses the testing of Aethlon Medical's novel affinity dialysis cartridge to remove HIV from cell culture fluids, plasma and from HIV-infected blood. Testing data documented that HIV from infected blood samples was captured with as great or greater efficiency than that of corresponding tests in cell culture fluid or plasma with 83 percent to 100 percent removal in an overnight dialysis.
The paper then describes the Aethlon Medical technology as a device that augments the function of the immune system through the physical removal of viruses and toxic proteins from the blood of infected patients. Physical removal of pathogens is precisely what biology accomplishes through humoral and cellular immune response. The device is a modified hemodialysis cartridge containing immobilized antibodies designed to replace or be used in a series with a standard dialysis cartridge. Because antibodies and other elements are covalently bound within the cartridge, minimal side effects may be expected.
The hypothesis of the authors is that the effective removal of infectious virus from circulation will prevent the reinfection of new host cells, analogous to the class of drugs known as entry inhibitors. At the same time, viral proteins should be reduced, thereby preventing immune cell loss due to innocent bystander and superantigen effects. In effect, Aethlon's affinity hemodialysis cartridge would function as an artificial lymph node. Moreover, because the technique is highly selective for HIV, it is entirely compatible with conventional drug therapy and most other treatments.
About Aethlon Medical
Aethlon Medical Inc. develops therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45 removes 55 percent of HIV from human blood in three hours and in excess of 85 percent in 12 hours. The AEMD-45 therapeutic device is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method of modifying artificial kidneys (hemodialysis cartridges) to mimic the immune systems response to clear infectious virus from circulation before healthy cells can be infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load, decrease the likelihood of treatment resistance, and treat without the side effects of current AIDS drugs. For more information, visit the company's Web site at www.AethlonMedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
CONTACT: Aethlon Medical Inc. James A. Joyce, 858/456-5777 jimjoyce@aethlonmedical.com
SOURCE: Aethlon Medical Inc.
020625
BW020616
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .